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multidimensionality of QoL can be assessed properly this way;
especially in this speciﬁc situation where the owners are proxy
reporters but also responsible for the well-being of the animal
and therefore likely to be biased.
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OBJECTIVE: A European STARR registry was set-up to deter-
mine the short-term safety and effectiveness of the STARR
procedure for obstructed defaecation syndrome. METHODS:
STARR registries in Italy, Germany and the UK were designed
with a web-based interface to allow pooling of results for com-
bined analysis. Recruitment commenced in January 2006. Data
collection included a symptom severity score (SSS), obstructed
defaecation score (ODS), Cleveland clinic incontinence score,
symptom-speciﬁc (PAC-QoL) and generic (ED-5Q utility and
VAS) QoL score. All complications were recorded. Data collec-
tion was performed at baseline, 6 weeks, and 6 and 12 months.
RESULTS: A total of 1456 patients were recruited and eligible
for analysis. There were 214 (14.7%) male patients. The mean
age was 54 yrs (range: 17–92). Mean operative time was 44mins
(range: 15–210). Average length of stay was 3 days (range:1–36).
By September 2007, 698 (48%) and 422 (29%) were eligible for
analysis at 6 and 12 months. respectively. A signiﬁcant symptom-
atic improvement was seen between baseline and 6 months and
maintained at 12 months (SSS: baseline 24.1 (95%CI: 23.8,24.4)
v’s 12 months 12.5 (95%CI: 12.1,12.9), p < 0.001; ODS: base-
line 15.3 (95%CI: 14.9,15.6) v’s 12 months 5.8 (95%CI:
4.8,6.7), p < 0.001. This was reﬂected in a signiﬁcant improve-
ment in both PAC-QoL and ED-5Q QoL scores at both 6 and
12 months. Incontinence scores improved from 3.1 (95%CI:
2.9,3.3) at baseline to 2.9 (95%CI: 2.1,2.7) at 6 months and
1.9 (95%CI: 1.5,2.2) at 12 months (p < 0.001). 457 minor and
major complications were reported, of which the most frequent
were: unexpected pain (7.7%), urinary retention (6.8%), bleed-
ing (4.5%), stapled line complications (3.2%), sepsis (1.4%),
incontinence (1.3%). Postoperative defaecatory urgency was
reported in 17% of patients. There was no mortality. CONCLU-
SION: STARR for ODS is safe,effective and signiﬁcant improve-
ment in QoL.
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OBJECTIVE: As part of a broader analysis on aging in the
community, the purpose is to perform a literature review to assess
the effectiveness of interventions designed to prevent falls and
fall-related injuries in community-dwelling elderly individuals.
METHODS: A search was performed in OVID MEDLINE,
MEDLINE In-Process and Other Non-Indexed Citations,
EMBASE, CINAHL, Cochrane Library, and INAHTA/NHS EED
between January 2000 and September 2007. Furthermore, all
studies included in a Cochrane review published in 2003 were
considered for inclusion. Studies were included if they were con-
trolled trials in a population of community dwelling elderly and
examined falls or fall-related injuries as an outcome. RESULTS:
Fifty-nine studies were identiﬁed investigating the effectiveness of
nine interventions. A meta-analysis found that exercise programs
effectively reduced falls if they were 6 months or longer in dura-
tion (RR = 0.84 [95% CI: 0.76–0.93]) or were offered to the
general population and not a high risk group (RR = 0.79 [0.70–
0.90]). Environmental modiﬁcations were effective in individuals
with a history of falls (RR = 0.66 [0.54–0.81]), and a gait
stabilizing device for outdoor winter use effectively reduced
falls (RR = 0.43 [0.29–0.64]) and injurious falls (RR = 0.10
[0.01–0.74]). Although neither hormone replacement therapy or
vitamin D alone reduced falls or injuries, vitamin D plus calcium
supplementation resulted in a reduction in the number of falls
(RR = 0.83 [0.73–0.95]) and fractures (RR = 0.60 [0.39, 0.94]).
Multifactorial interventions were only marginally effective in
reducing falls in a high risk population (RR = 0.87 [0.76–1.01]),
and there was no evidence that vision interventions or hip pro-
tectors were effective. CONCLUSION: Several interventions
were identiﬁed which reduce the risk of falls and fall-related
injuries in community-dwelling elderly, however special con-
sideration must be given to the intervention duration and
population risk proﬁle when determining the most appropriate
interventions to implement. An economic analysis that informs
investment decisions to maximize the impact of reducing falls is
currently underway.
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OBJECTIVE: Contraceptive efﬁcacy depends both on patient
compliance and the characteristics of the method used. Efﬁcacy
rates can thus vary across different populations, particularly in
women employing user-dependent methods (i.e., oral, condoms).
This study measured the contraceptive failure rates in a Medicaid
and a non-Medicaid population and evaluated the efﬁcacy
variance between the two groups. METHODS: Monthly
contraceptive-use histories were constructed for all women using
data from the 2002 National Survey of Family Growth (NSFG
VI). Contraceptive use was deﬁned by ﬁrst contraception method
mentioned in the survey. Poly-modal use was not deﬁned.
Women were classiﬁed as Medicaid enrollees if they reported
having Medicaid coverage in the 12 months prior to the survey,
or reported Medicaid payment for services. The ﬁnal dataset
included 1208 Medicaid-enrolled women and 6435 non-
Medicaid enrolled women. Pregnancy rates were calculated each
month and then annualized for women using user-dependent
methods (oral contraceptives [OC], condom) or non-daily
methods (IUD, injected, implanted birth control). RESULTS:
Average annual contraceptive failure rates for Medicaid vs. non-
Medicaid women were: oral pill—1.15% vs 0.13% (p = 0.0051);
condom—2.05% vs. 0.55% (p = 0.0015); IUD—0.52% vs.
0.16% (p = 0.5156); injected or implanted—0.27% vs. 0.13%
(p = 0.3940). OC failure rate was nearly 9-times higher in the
Medicaid population than in the non-Medicaid population. Fail-
ures rates for IUD, injectables and implants were also higher but
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